Volker Sandig - Search Results

Year	Number of Results
2003	1
2004	1
2005	1
2008	1
2009	3
2010	3
2011	17
2012	6
2013	3
2014	3
2015	1
2016	2
2017	2
2018	2
2019	6
2020	3
2022	4
2023	2

1

Matrix and backstage: cellular substrates for viral vaccines.

Jordan I, Sandig V. Jordan I, et al. Among authors: sandig v. Viruses. 2014 Apr 11;6(4):1672-700. doi: 10.3390/v6041672. Viruses. 2014. PMID: 24732259 Free PMC article. Review.

2

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara.

Jordan I, Lohr V, Genzel Y, Reichl U, Sandig V. Jordan I, et al. Among authors: sandig v. Microorganisms. 2013 Nov 1;1(1):100-121. doi: 10.3390/microorganisms1010100. Microorganisms. 2013. PMID: 27694766 Free PMC article. Review.

3

High-cell-density cultivations to increase MVA virus production.

Vázquez-Ramírez D, Genzel Y, Jordan I, Sandig V, Reichl U. Vázquez-Ramírez D, et al. Among authors: sandig v. Vaccine. 2018 May 24;36(22):3124-3133. doi: 10.1016/j.vaccine.2017.10.112. Epub 2018 Feb 9. Vaccine. 2018. PMID: 29433897 Free PMC article.

4

Forced Degradation Testing as Complementary Tool for Biosimilarity Assessment.

Dyck YFK, Rehm D, Joseph JF, Winkler K, Sandig V, Jabs W, Parr MK. Dyck YFK, et al. Among authors: sandig v. Bioengineering (Basel). 2019 Jul 21;6(3):62. doi: 10.3390/bioengineering6030062. Bioengineering (Basel). 2019. PMID: 31330921 Free PMC article.

5

Applying Acylated Fucose Analogues to Metabolic Glycoengineering.

Rosenlöcher J, Böhrsch V, Sacharjat M, Blanchard V, Giese C, Sandig V, Hackenberger CPR, Hinderlich S. Rosenlöcher J, et al. Among authors: sandig v. Bioengineering (Basel). 2015 Nov 30;2(4):213-234. doi: 10.3390/bioengineering2040213. Bioengineering (Basel). 2015. PMID: 28952479 Free PMC article.

6

Fucose-targeted glycoengineering of pharmaceutical cell lines.

Ogorek C, Jordan I, Sandig V, von Horsten HH. Ogorek C, et al. Among authors: sandig v. Methods Mol Biol. 2012;907:507-17. doi: 10.1007/978-1-61779-974-7_29. Methods Mol Biol. 2012. PMID: 22907371

7

Cell-line screening and process development for a fusogenic oncolytic virus in small-scale suspension cultures.

Göbel S, Kortum F, Chavez KJ, Jordan I, Sandig V, Reichl U, Altomonte J, Genzel Y. Göbel S, et al. Among authors: sandig v. Appl Microbiol Biotechnol. 2022 Aug;106(13-16):4945-4961. doi: 10.1007/s00253-022-12027-5. Epub 2022 Jun 29. Appl Microbiol Biotechnol. 2022. PMID: 35767011 Free PMC article.

8

Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans.

Dekkers G, Plomp R, Koeleman CA, Visser R, von Horsten HH, Sandig V, Rispens T, Wuhrer M, Vidarsson G. Dekkers G, et al. Among authors: sandig v. Sci Rep. 2016 Nov 22;6:36964. doi: 10.1038/srep36964. Sci Rep. 2016. PMID: 27872474 Free PMC article.

9

Development of an efficient veterinary rabies vaccine production process in the avian suspension cell line AGE1.CR.pIX.

Trabelsi K, Zakour MB, Jordan I, Sandig V, Rourou S, Kallel H. Trabelsi K, et al. Among authors: sandig v. BMC Biotechnol. 2022 Jun 17;22(1):17. doi: 10.1186/s12896-022-00747-5. BMC Biotechnol. 2022. PMID: 35715843 Free PMC article.

10

A clinically validated, broadly active, oral viral superinfection therapy could mitigate symptoms in early-stage COVID-19 patients.

Bakacs T, Sandig V, Slavin S, Gumrukcu S, Hardy WD, Renz W, Kovesdi I. Bakacs T, et al. Among authors: sandig v. Infect Disord Drug Targets. 2022 Apr 19. doi: 10.2174/1871526522666220419130403. Online ahead of print. Infect Disord Drug Targets. 2022. PMID: 35440336

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

56 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year